Swiss pharma giant Roche, the parent company of gene therapy pioneer Genentech, announced this week that it is divesting Genentech's 427K SF facility in Vacaville, the largest bio-manufacturing plant in the US.
Roche said it hopes to find a "suitable buyer" for the manufacturing site but said the decision would have no immediate effect on employees or operations at the Vacaville facility, according to a report in the San Francisco Business Times.
"We aim to find a buyer who shares our values and respects the contributions and expertise of our colleagues at the facility," Susanne Hundsbaek-Pederson, global head of pharma technical operations for Roche, said in a statement.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
